Stay updated on Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check45 days agoChange DetectedThe webpage has updated its content to reflect new classifications for Uterine Corpus Carcinoma and related neoplasms, while also removing outdated references. Additionally, there is a notice regarding heavy traffic affecting service performance.SummaryDifference2%
- Check52 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.0%
- Check67 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.0%
- Check74 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.1%
- Check96 days agoChange DetectedThe website has added new dates for December 2024 while removing several October 2024 entries, including the last update posted.SummaryDifference0.4%
Stay in the know with updates to Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.